.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing patients with hereditary cancer syndromes requires precise risk data. Recent research has significantly clarified ATM variant cancer risks, providing clinicians with robust hazard ratios (HR) and cumulative risk estimates. Furthermore, this data is vital for families carrying pathogenic or predicted pathogenic variants (PV/PPV) of the ATM gene, as it informs the timing of life-saving screenings.
Specifically, researchers observed a four-fold increase in the risk of female breast cancer (HR 4.0) within a large cohort of 141 ataxia-telangiectasia families. Consequently, clinicians must prioritize specialized screening for this high-risk group. Additionally, the risk for pancreatic cancer was notably elevated, with hazard ratios of 6.6 for females and 2.8 for males. However, this study noted that these risk patterns remained similar across various family settings.
Regarding cumulative risks, the data provides a clear timeline for intervention. Moreover, for women born between 1960 and 1969, the breast cancer risk reaches 9.9% by age 50 and 40% by age 80. Notably, the lifetime risk of pancreatic cancer by age 80 is approximately 8.1% for females and 5.1% for males. This study showed no statistically significant increase in the risk of ovarian or prostate cancers, focusing clinical attention on the breast and pancreas.
The primary risks involve female breast cancer and pancreatic cancer for both genders. Female heterozygotes face a significantly higher hazard ratio compared to the general population.
According to this specific cohort analysis, there was no statistically significant increase in ovarian or prostate cancer risks for ATM variant carriers.
While management is personalized, many guidelines suggest starting annual breast MRIs by age 30-35 and pancreatic surveillance by age 50 in those with a family history.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Jiao Y et al. Cancer risks for ATM variant heterozygotes. Genet Med. 2026 Apr 28. doi: undefined. PMID: 42052916.
2. ACMG Clinical Practice Resource. Management of individuals with heterozygous germline pathogenic variants in ATM. Genet Med. 2025 Jan.
3. NCCN Guidelines. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ATM variant carriers face higher risks for breast and pancreatic cancers, with female cumulative breast cancer risk reaching 40% by age 80....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
